research A multicentre trial of the epilation efficacy of a new, large spot size, constant spectrum emission IPL device
The IPL device is safe, effective, and has high patient satisfaction for hair removal.
Search
for
Sort by
Research
30 / 1000+ results research A Multi‐Center Clinical Trial to Evaluate the Efficacy of the Next Generation TriHex Technology Antiaging Regimen
The serum improves facial skin quality safely and effectively.
research Multicenter double blind randomized placebo controlled clinical trial of minoxidil gel in the treatment of alopecia areata
2.2% minoxidil gel effectively and safely treats alopecia areata.
research A multicentre placebo‐controlled clinical trial on the efficacy of oral ciclosporin A in the treatment of canine idiopathic sebaceous adenitis in comparison with conventional topical treatment
Oral ciclosporin A and topical treatments both reduce hair loss and scaling in dogs with sebaceous adenitis, but using both together is most effective.
research Safety and Efficacy of Mesotherapy with Placenta Polypeptide Injection for Moderate-to-Severe Sensitive Skin: A Multicenter, Randomized, Controlled Trial
Placenta polypeptide injection is a safe and effective treatment for sensitive skin.
research Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial
Bariatric surgery improves ovulation rates in women with PCOS and obesity better than medical therapy.
research A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss.
5% minoxidil foam is effective and safe for hair regrowth in women with hair loss.
research A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
New 5% minoxidil foam effectively promotes hair growth and is safe for use.
research An open label, multi-center clinical trial of topical 5% minoxidil solution for the treatment of male androgenetic alopecia (a phase IV study)
Topical 5% minoxidil is safe and effective for treating hair loss in Korean men.
research The effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial
YH0618 granule may help prevent hair loss in breast cancer patients undergoing chemotherapy.
research Safety and biopsy outcomes of a topical treatment (SM04554) for male androgenetic alopecia (AGA): Results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial
Topical treatment SM04554 safely promotes hair growth in male baldness.
research Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial
Fibrinogen/LDL apheresis may improve speech perception in sudden hearing loss, especially for those with high fibrinogen and LDL levels.
research Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild‐to‐moderate alopecia areata: A multicenter, prospective, randomized, controlled, investigator‐blinded trial
Betamethasone valerate foam is more effective and safe for treating mild-to-moderate alopecia areata than betamethasone dipropionate lotion.
research Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial
The trial will test if YH0618 granule prevents hair loss in breast cancer patients during chemotherapy.
research Clinical Efficacy, Cosmetic Acceptability, and Local Tolerability of a New Formulation of Topical 5% Minoxidil without Propylene glycol: A 6-month, Multicentre, Real-life, Prospective, Assessor-Blinded Study in 196 Subjects with Hair Loss. The andldquo;NOMINALandrdquo; Trial
The new 5% minoxidil formulation without propylene glycol effectively promotes hair growth with fewer side effects and better user satisfaction.
research The “NOMINAL” trial: Clinical efficacy, cosmetic acceptability, and local tolerability of topical 5% minoxidil lotion without propylene glycol: A 6-month, multicentre, real-life, prospective, assessor-blinded study in 196 subjects with hair loss.
The 5% minoxidil lotion without propylene glycol is effective, well-tolerated, and cosmetically acceptable for hair loss.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial
Low-dose dutasteride effectively and safely promotes hair growth in men.
research Faculty Opinions recommendation of Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial.
Low-level light therapy significantly increased hair density and thickness in people with hair loss, but they didn't notice a difference.
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
research Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial
Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
research The efficacy and safety of BM-PHA for the correction of nasolabial folds: a multicenter, randomized, double-blind, split-face clinical trial
BM-PHA is as effective and safe as Restylane Perlane for improving nasolabial folds with minor side effects.
research Supplementary Material for: Turpentine ointment for the treatment of folliculitis – an open, prospective, randomized, placebo- and comparator-controlled multicenter trial
Turpentine ointment is effective and safe for treating folliculitis.
research Supplementary Material for: Turpentine ointment for the treatment of folliculitis – an open, prospective, randomized, placebo- and comparator-controlled multicenter trial
Turpentine ointment is an effective and safe treatment for folliculitis.
research Efficacy and Safety of Polycaprolactone in Treating Nasolabial Folds: A Prospective, Multicenter, and Randomized Controlled Trial
Polycaprolactone gel is effective and safe for treating nasolabial folds.
research Efficacy and safety of a domestic hair follicle extraction system in extracting hair follicles from patients with androgenetic alopecia: a multicenter, prospective, randomized, self-controlled clinical trial
The domestic hair follicle extraction system is as effective and safe as traditional FUE.
research Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial
YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
research Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial
YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
research Effect and mechanism of YH0618 granule on chemotherapy- induced hair loss in patients with breast cancer: study protocol for a randomized, double-blind, multi-center clinical trial
YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
research The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial
DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.